Northern Trust Corp Buys 390,190 Shares of Alto Neuroscience, Inc. (NYSE:ANRO)

Northern Trust Corp raised its position in shares of Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) by 198.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 587,135 shares of the company's stock after acquiring an additional 390,190 shares during the quarter. Northern Trust Corp owned approximately 2.18% of Alto Neuroscience worth $2,484,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of ANRO. Boothbay Fund Management LLC lifted its position in Alto Neuroscience by 1,941.1% during the fourth quarter. Boothbay Fund Management LLC now owns 103,100 shares of the company's stock valued at $436,000 after buying an additional 108,700 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Alto Neuroscience by 4.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 844,823 shares of the company's stock worth $3,575,000 after buying an additional 36,319 shares during the period. Stifel Financial Corp bought a new position in shares of Alto Neuroscience in the 4th quarter worth about $544,000. Marshall Wace LLP purchased a new position in Alto Neuroscience during the 4th quarter valued at about $3,542,000. Finally, Barclays PLC lifted its position in Alto Neuroscience by 34.5% during the 4th quarter. Barclays PLC now owns 39,807 shares of the company's stock valued at $168,000 after acquiring an additional 10,208 shares during the period.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ANRO. Wedbush reaffirmed a "neutral" rating and set a $4.00 target price on shares of Alto Neuroscience in a research note on Thursday, May 15th. William Blair reaffirmed an "outperform" rating on shares of Alto Neuroscience in a research report on Friday, March 21st. Finally, HC Wainwright started coverage on Alto Neuroscience in a research note on Monday, April 7th. They set a "buy" rating and a $10.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Alto Neuroscience has an average rating of "Moderate Buy" and a consensus target price of $15.40.

Alto Neuroscience Stock Down 5.3%

Shares of NYSE ANRO traded down $0.16 during midday trading on Tuesday, hitting $2.87. The stock had a trading volume of 176,004 shares, compared to its average volume of 385,506. The business's 50 day moving average is $2.35 and its 200-day moving average is $3.38. Alto Neuroscience, Inc. has a 52 week low of $1.60 and a 52 week high of $17.55. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. The company has a market cap of $77.70 million, a P/E ratio of -1.23 and a beta of 1.87.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.06. As a group, analysts predict that Alto Neuroscience, Inc. will post -2.54 EPS for the current year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.